My research interests lie at the interface of pharmacology,
neuroscience, and psychiatry. Prevention and treatment of
neuropsychiatric disorders could be greatly advanced by a more
comprehensive understanding of the biology of impulsivity. Our group is
focused on deciphering the patterns of individual differences in
behavioral disinhibition and decision-making seen with respect to the
development and maintenance of chronic neuropsychiatric disorders. In
particular, we focus on glutamatergic neurotransmission and
disinhibition of cortical top-down output in different facets of
impulsive-compulsive traits. There is evidence that glutamate
neurotransmission through the ionotropic glutamate N-methyl-D-aspartate
receptor plays a key role in the cognitive and/or behavioral dimensions
of impulsivity and addictive behaviors, perhaps within the
corticostriatal circuit, a network integral to decision-making and
goal-directed behavior. An additional focus of the laboratory is to
determine that neuronal serotonin and glutamate systems mechanistically
converge to govern impulsivity and that rebalancing these systems may
ultimately support behavioral recovery in disorders marked by
impulsivity concomitant with an imbalance in the reward system and
reactivity to reward conditioned cues (e.g., psychostimulant addiction,
binge-eating disorder, obesity).
We employ a multi-disciplinary
approach (e.g., biochemistry, gene-mediated viral delivery, behavioral
models, cellular models) to elucidate the neurobiological substrates
(e.g., receptor trafficking, protein:protein interactions, epigenetic
modifications) within the corticostriatal circuit that drive the
vulnerable vs. resistant phenotypes underlying dysregulated drug- and
feeding-related behaviors as assessed in the preclinical environment.